BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9145244)

  • 1. Effects of an inhibitor of cathepsin L on bone resorption in thyroparathyroidectomized and ovariectomized rats.
    Millest AJ; Breen SA; Loveday BE; Clarkson PN; Simpson CA; Waterton JC; Johnstone D
    Bone; 1997 May; 20(5):465-71. PubMed ID: 9145244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized rat.
    Lark MW; Stroup GB; James IE; Dodds RA; Hwang SM; Blake SM; Lechowska BA; Hoffman SJ; Smith BR; Kapadia R; Liang X; Erhard K; Ru Y; Dong X; Marquis RW; Veber D; Gowen M
    Bone; 2002 May; 30(5):746-53. PubMed ID: 11996914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
    Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
    J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Participation of cathepsin L on bone resorption.
    Kakegawa H; Nikawa T; Tagami K; Kamioka H; Sumitani K; Kawata T; Drobnic-Kosorok M; Lenarcic B; Turk V; Katunuma N
    FEBS Lett; 1993 Apr; 321(2-3):247-50. PubMed ID: 8477857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
    Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
    J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppressive effect of N-(benzyloxycarbonyl)-L-phenylalanyl-L-tyrosinal on bone resorption in vitro and in vivo.
    Woo JT; Yamaguchi K; Hayama T; Kobori T; Sigeizumi S; Sugimoto K; Kondo K; Tsuji T; Ohba Y; Tagami K; Sumitani K
    Eur J Pharmacol; 1996 Apr; 300(1-2):131-5. PubMed ID: 8741178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent and selective cathepsin L inhibitors do not inhibit human osteoclast resorption in vitro.
    James IE; Marquis RW; Blake SM; Hwang SM; Gress CJ; Ru Y; Zembryki D; Yamashita DS; McQueney MS; Tomaszek TA; Oh HJ; Gowen M; Veber DF; Lark MW
    J Biol Chem; 2001 Apr; 276(15):11507-11. PubMed ID: 11148212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
    Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
    J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of peptide aldehyde derivatives as selective inhibitors of human cathepsin L and their inhibitory effect on bone resorption.
    Yasuma T; Oi S; Choh N; Nomura T; Furuyama N; Nishimura A; Fujisawa Y; Sohda T
    J Med Chem; 1998 Oct; 41(22):4301-8. PubMed ID: 9784105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
    Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
    J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory activity of Drynariae rhizoma extracts on cathepsin having bone resorption activity.
    Jeong JC; Yoon CH; Jeong CW; Lee YC; Chang YC; Kim CH
    Immunopharmacol Immunotoxicol; 2004 Aug; 26(3):373-85. PubMed ID: 15518171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of human recombinant calcitonin on a rat osteopenia model induced by TPTX and arotinoid.
    Fukuda C; Oizumi K; Ohhata K; Kiyokawa A; Katsumata M; Ishikawa H; Miyamoto M
    Calcif Tissue Int; 2002 Jul; 71(1):80-7. PubMed ID: 12200658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of collagenolytic cathepsins by beta-lactoglobulin in milk and its suppressive effect on bone resorption.
    Ogawa N; Takahashi M; Ishidoh K; Katunuma N
    J Nutr Sci Vitaminol (Tokyo); 2009 Jun; 55(3):264-70. PubMed ID: 19602835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of apolipoprotein E degradation in a post-Golgi compartment by a cysteine protease inhibitor.
    Ye SQ; Reardon CA; Getz GS
    J Biol Chem; 1993 Apr; 268(12):8497-502. PubMed ID: 8473293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L.
    Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD
    J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K.
    Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT
    J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
    Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
    Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both thyroparathyroidectomized and ovariectomized rats.
    Visentin L; Dodds RA; Valente M; Misiano P; Bradbeer JN; Oneta S; Liang X; Gowen M; Farina C
    J Clin Invest; 2000 Jul; 106(2):309-18. PubMed ID: 10903347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin B and L activities in isolated osteoclasts.
    Rifkin BR; Vernillo AT; Kleckner AP; Auszmann JM; Rosenberg LR; Zimmerman M
    Biochem Biophys Res Commun; 1991 Aug; 179(1):63-9. PubMed ID: 1883385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones.
    Xia L; Kilb J; Wex H; Li Z; Lipyansky A; Breuil V; Stein L; Palmer JT; Dempster DW; Brömme D
    Biol Chem; 1999 Jun; 380(6):679-87. PubMed ID: 10430032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.